Z-DQMD-FMK
Need Assistance?
  • US & Canada:
    +
  • UK: +

Z-DQMD-FMK

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Z-DQMD-FMK has been found to be a Caspase-3 inhibitor and could induce small cell lung cancer cell death in vitro.

Category
Peptide Inhibitors
Catalog number
BAT-010378
CAS number
767287-99-0
Molecular Formula
C29H40FN5O11S
Molecular Weight
685.72
Z-DQMD-FMK
IUPAC Name
methyl (3S)-3-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-methoxy-4-oxo-2-(phenylmethoxycarbonylamino)butanoyl]amino]-5-oxopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-fluoro-4-oxopentanoate
Synonyms
Z-D(OMe)QMD(OMe)-fmk; benzyloxycarbonyl-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone; Z-Asp(OMe)-Gln-Met-Asp(OMe) fluoromethyl ketone; L-Methioninamide, N-[(phenylmethoxy)carbonyl]-L-alpha-aspartyl-L-glutaminyl-N-[(1S)-3-fluoro-1-(2-methoxy-2-oxoethyl)-2-oxopropyl]-, methyl ester; methyl (5S,8S,11S,14S)-8-(3-amino-3-oxopropyl)-14-(2-fluoroacetyl)-5-(2-methoxy-2-oxoethyl)-11-(2-(methylthio)ethyl)-3,6,9,12-tetraoxo-1-phenyl-2-oxa-4,7,10,13-tetraazahexadecan-16-oate
Appearance
White Powder
Purity
≥95%
Density
1.3±0.1 g/cm3
Boiling Point
1028.9±65.0°C at 760 mmHg
Sequence
Cbz-Asp(OMe)-Gln-Met-Asp(OMe)-FMK
Storage
Store at -20°C
Solubility
Soluble in DMSO
InChI
InChI=1S/C29H40FN5O11S/c1-44-24(38)13-20(22(36)15-30)34-27(41)19(11-12-47-3)33-26(40)18(9-10-23(31)37)32-28(42)21(14-25(39)45-2)35-29(43)46-16-17-7-5-4-6-8-17/h4-8,18-21H,9-16H2,1-3H3,(H2,31,37)(H,32,42)(H,33,40)(H,34,41)(H,35,43)/t18-,19-,20-,21-/m0/s1
InChI Key
QFITYVNVMNJELE-TUFLPTIASA-N
Canonical SMILES
COC(=O)CC(C(=O)CF)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CC(=O)OC)NC(=O)OCC1=CC=CC=C1
1. Mitochondrial fission leads to Smac/DIABLO release quenched by ARC
Danian Qin, Ruediger von Harsdorf, Jincheng Li, Yanrui Li, Peifeng Li Apoptosis . 2010 Oct;15(10):1187-96. doi: 10.1007/s10495-010-0514-8.
Apoptosis plays a critical role for the development of a variety of cardiac diseases. Cardiomyocytes are enriched in mitochondria, while mitochondrial fission can regulate apoptosis. The molecular mechanism governing cardiomyocyte apoptosis remain to be fully elucidated. Our results showed that Smac/DIABLO is necessary for apoptosis in cardiomyocytes, and it is released from mitochondria into cytosol in response to apoptotic stimulation. Smac/DIABLO release is a consequence of mitochondrial fission mediated by dynamin-related protein-1 (Drp1). Upon release Smac/DIABLO binds to X-linked inhibitor of apoptosis protein (XIAP), resulting in the activation of caspase-9 and caspase-3. Their activation is a prerequisite for the initiation of apoptosis because the administration of z-LEHD-fmk and z-DQMD-fmk, two relatively specific inhibitors for caspase-9, and caspase-3, respectively, could significantly attenuate apoptosis. Smac/DIABLO release could not be blocked by these caspase inhibitors, indicating that it is an event upstream of caspase activation. ARC (apoptosis repressor with caspase recruitment domain), an abundantly expressed apoptotic repressor in cardiomyocytes, could inhibit mitochondrial fission and Smac/DIABLO release. Our data reveal that Smac/DIABLO is a target of ARC in counteracting apoptosis.
2. Non-phosphorylated FTY720 induces apoptosis of human microglia by activating SREBP2
Takashi Yoshino, Seung U Kim, Jun-Ichi Satoh, Hiroko Tabunoki, Shigeo Sugiyama, Keitaro Ishii Cell Mol Neurobiol . 2011 Oct;31(7):1009-20. doi: 10.1007/s10571-011-9698-x.
A synthetic analog of sphingosine named FTY720 (Fingolimod), phosphorylated by sphingosine kinase-2, interacts with sphingosine-1-phosphate (S1P) receptors expressed on various cells. FTY720 suppresses the disease activity of multiple sclerosis (MS) chiefly by inhibiting S1P-dependent egress of autoreactive T lymphocytes from secondary lymphoid organs, and possibly by exerting anti-inflammatory and neuroprotective effects directly on brain cells. However, at present, biological effects of FTY720 on human microglia are largely unknown. We studied FTY720-mediated apoptosis of a human microglia cell line HMO6. The exposure of HMO6 cells to non-phosphorylated FTY720 (FTY720-non-P) induced apoptosis in a dose-dependent manner with IC50 of 10.6 ± 2.0 μM, accompanied by the cleavage of caspase-7 and caspase-3 but not of caspase-9. The apoptosis was inhibited by Z-DQMD-FMK, a caspase-3 inhibitor, but not by Pertussis toxin, a Gi protein inhibitor, suramin, a S1P3/S1P5 inhibitor, or W123, a S1P1 competitive antagonist, although HMO6 expressed S1P1, S1P2, and S1P3. Furthermore, both phosphorylated FTY720 (FTY720-P) and SEW2871, S1P1 selective agonists, did not induce apoptosis of HMO6. Genome-wide gene expression profiling and molecular network analysis indicated activation of transcriptional regulation by sterol regulatory element-binding protein (SREBP) in FTY720-non-P-treated HMO6 cells. Western blot verified activation of SREBP2 in these cells, and apoptosis was enhanced by pretreatment with simvastatin, an activator of SREBP2, and by overexpression of the N-terminal fragment of SREBP2. These observations suggest that FTY720-non-P-induced apoptosis of HMO6 human microglia is independent of S1P receptor binding, and positively regulated by the SREBP2-dependent proapoptotic signaling pathway.
3. Inhibiting caspase-3 activity blocks beta-catenin degradation after focal ischemia in rat
Takayoshi Shimohata, Xuwen Gao, Chuancheng Ren, Heng Zhao, Zhimin Yan, Gary K Steinberg, Hanfeng Zhang Neuroreport . 2008 May 28;19(8):821-4. doi: 10.1097/WNR.0b013e3282ffda72.
Beta-catenin can be cleaved by caspase-3 or degraded by activated glycogen synthase kinase-3beta via phosphorylating beta-catenin. We tested the hypothesis that beta-catenin undergoes degradation after stroke, and its degradation is dependent on caspase activity. Stroke was generated by permanent middle cerebral artery occlusion and 1 h of transient bilateral common carotid artery occlusion in rats. Active caspase-3 was expressed in the ischemic cortex from 5 to 48 h after stroke, whereas beta-catenin markedly degraded at 24 and 48 h after stroke. The caspase 3-specific inhibitor, Z-DQMD-FMK, attenuated beta-catenin degradation, but it did not affect phosphorylation of both beta-catenin and glycogen synthase kinase-3beta. In conclusion, beta-catenin degraded after stroke, and its degradation was caspase-3 dependent.
Online Inquiry
Verification code
Inquiry Basket